Biotech Values

[genisi]

The other interesting speculation is whether there is any correlation between PD-L1 expression and outcomes for immune therapies like Dendreon's.

I'd think that PD-L1 over/aberrant expression on tumors (not peripheral-blood T cells), is in general a marker for poor prognosis as it indicates down-regulation of the immune response and so could also impair the therapeutic mechanism of Provenge. Makes sense that an anti-PD-1 would enhances Provenge or other immunotherapy response. The next question that comes to mind is what would work best in combo with an anti-PD-1. I see that Bristol is testing several combinations:

http://clinicaltrials.gov/ct2/results?term=BMS-936558+combination&Search=Search